Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) General Counsel Elizabeth Rozek sold 10,914 shares of the company’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $3.10, for a total transaction of $33,833.40. Following the transaction, the general counsel now owns 160,506 shares in the company, valued at $497,568.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Sagimet Biosciences Stock Up 5.5 %
Shares of SGMT stock traded up $0.17 during trading hours on Tuesday, hitting $3.26. 163,685 shares of the company were exchanged, compared to its average volume of 1,065,808. The business has a 50 day moving average of $4.15 and a two-hundred day moving average of $5.58. Sagimet Biosciences Inc. has a 52 week low of $2.13 and a 52 week high of $20.71.
Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.18. As a group, equities research analysts predict that Sagimet Biosciences Inc. will post -1.76 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Analysis on SGMT
Hedge Funds Weigh In On Sagimet Biosciences
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Sagimet Biosciences by 364.9% during the first quarter. Vanguard Group Inc. now owns 1,139,407 shares of the company’s stock worth $6,176,000 after acquiring an additional 894,319 shares during the period. Ikarian Capital LLC bought a new stake in shares of Sagimet Biosciences during the 1st quarter valued at approximately $2,236,000. Federated Hermes Inc. grew its holdings in shares of Sagimet Biosciences by 24.7% during the 4th quarter. Federated Hermes Inc. now owns 97,276 shares of the company’s stock valued at $527,000 after purchasing an additional 19,276 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Sagimet Biosciences by 215.0% during the 4th quarter. Victory Capital Management Inc. now owns 56,570 shares of the company’s stock valued at $307,000 after purchasing an additional 38,610 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Sagimet Biosciences during the 1st quarter valued at approximately $188,000. 87.86% of the stock is owned by institutional investors.
About Sagimet Biosciences
Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
See Also
- Five stocks we like better than Sagimet Biosciences
- 3 Ways To Invest In Coffee, Other Than Drinking It
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Stock Dividend Cuts Happen Are You Ready?
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- What Are Dividend Contenders? Investing in Dividend Contenders
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.